Improving the Specificity of Screening for Lethal Prostate Cancer Using Prostate-specific Antigen and a Panel of Kallikrein Markers: A Nested Case-Control Study

European Urology

Volumn 68, Issue 2, 2015, Pages 207-213

  Stattin, Pär ^a   Vickers, Andrew J ^b   Sjoberg, Daniel D ^b   Johansson, Robert ^a   Granfors, Torvald ^c   Johansson, Mattias ^d   Pettersson, Kim ^e   Scardino, Peter T ^b   Hallmans, Göran ^a   Lilja, Hans ^b,f,g  

^a UMEÅ UNIVERSITY   (Sweden)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c ST GÖRAN S HOSPITAL   (Sweden)

^d INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^e UNIVERSITY OF TURKU   (Finland)

^f UNIVERSITY OF OXFORD   (United Kingdom)

^g LUND UNIVERSITY   (Sweden)

Author keywords

Cancer metastasis; Kallikrein related peptidases; Prostate biopsy; Prostate cancer; Prostate specific antigen

Indexed keywords

KALLIKREIN; PROSTATE SPECIFIC ANTIGEN; KALLIKREIN-RELATED PEPTIDASE 3, HUMAN;

ADULT; ARTICLE; CANCER RISK; CANCER SCREENING; CANCER STAGING; CASE CONTROL STUDY; COHORT ANALYSIS; CONTROLLED STUDY; CRYOPRESERVATION; DISTANT METASTASIS; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; BIOPSY; BLOOD; CANCER GRADING; DECISION SUPPORT SYSTEM; EARLY CANCER DIAGNOSIS; EPIDEMIOLOGY; METASTASIS; MIDDLE AGED; MORTALITY; PATHOLOGY; PATIENT SELECTION; PREDICTIVE VALUE; PROCEDURES; PROSTATE TUMOR; REGISTER; RISK ASSESSMENT; RISK FACTOR; SWEDEN; TIME FACTOR; UPREGULATION;

ADULT; BIOPSY; CASE-CONTROL STUDIES; DECISION SUPPORT TECHNIQUES; EARLY DETECTION OF CANCER; HUMANS; KALLIKREINS; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM METASTASIS; NEOPLASM STAGING; PATIENT SELECTION; PREDICTIVE VALUE OF TESTS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; REGISTRIES; RISK ASSESSMENT; RISK FACTORS; SWEDEN; TIME FACTORS; UP-REGULATION;

EID: 84937514041     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2015.01.009     Document Type: Article

References (28)

1. F.H. Schroder, J. Hugosson, M.J. Roobol, and et al. Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up Lancet 384 2014 2027 2035
2. J. Hugosson, S. Carlsson, G. Aus, and et al. Mortality results from the Goteborg randomised population-based prostate-cancer screening trial Lancet Oncol 11 2010 725 732
3. G. Hallmans, A. Agren, G. Johansson, and et al. Cardiovascular disease and diabetes in the Northern Sweden Health and Disease Study Cohort-evaluation of risk factors and their interactions Scand J Public Health Suppl 61 2003 18 24
4. L. Weinehall, C.G. Hallgren, G. Westman, U. Janlert, and S. Wall Reduction of selection bias in primary prevention of cardiovascular disease through involvement of primary health care Scand J Prim Health Care 16 1998 171 176
5. B. Pilebro, R. Johansson, L. Damber, J.E. Damber, and P. Stattin Population-based study of prostate-specific antigen testing and prostate cancer detection in clinical practice in northern Sweden Scand J Urol Nephrol 37 2003 210 212
6. K. Mitrunen, K. Pettersson, T. Piironen, T. Bjork, H. Lilja, and T. Lovgren Dual-label one-step immunoassay for simultaneous measurement of free and total prostate-specific antigen concentrations and ratios in serum Clin Chem 41 1995 1115 1120
7. V. Vaisanen, M.T. Peltola, H. Lilja, M. Nurmi, and K. Pettersson Intact free prostate-specific antigen and free and total human glandular kallikrein 2. Elimination of assay interference by enzymatic digestion of antibodies to F(ab′)2 fragments Anal Chem 78 2006 7809 7815
8. A. Vickers, A. Cronin, M. Roobol, and et al. Reducing unnecessary biopsy during prostate cancer screening using a four-kallikrein panel: an independent replication J Clin Oncol 28 2010 2493 2498
9. J.A. Lane, J.L. Donovan, M. Davis, and et al. Active monitoring, radical prostatectomy, or radiotherapy for localised prostate cancer: study design and diagnostic and baseline results of the ProtecT randomised phase 3 trial Lancet Oncol 15 2014 1109 1118
10. Bryant RJ, Sjoberg DD, Vickers AJ, et al. Predicting high-grade cancer at ten-core prostate biopsy using four kallikrein markers measured in blood in the ProtecT study. J Natl Cancer Inst. In press.
11. A.J. Vickers, A.M. Cronin, T. Bjork, and et al. Prostate specific antigen concentration at age 60 and death or metastasis from prostate cancer: case-control study BMJ 341 2010 c4521
12. A.J. Vickers, D. Ulmert, D.D. Sjoberg, and et al. Strategy for detection of prostate cancer based on relation between prostate specific antigen at age 40-55 and long term risk of metastasis: case-control study BMJ 346 2013 f2023
13. R.G. Casey, P.K. Hegarty, R. Conroy, and et al. The distribution of PSA age-specific profiles in healthy Irish men between 20 and 70 ISRN Oncol 2012 2012 832109
14. J.R. Anderson, D. Strickland, D. Corbin, J.A. Byrnes, and E. Zweiback Age-specific reference ranges for serum prostate-specific antigen Urology 46 1995 54 57
15. L.A. Kalish, and J.B. McKinlay Serum prostate-specific antigen levels (PSA) in men without clinical evidence of prostate cancer: age-specific reference ranges for total PSA, free PSA, and percent free PSA Urology 54 1999 1022 1027
16. S. Loeb, H.B. Carter, W.J. Catalona, J.W. Moul, and F.H. Schroder Baseline prostate-specific antigen testing at a young age Eur Urol 61 2012 1 7
17. E.A. Vertosick, B.Y. Poon, and A.J. Vickers Relative value of race, family history and prostate specific antigen as indications for early initiation of prostate cancer screening J Urol 192 2014 724 728
18. B. Rockhill, D. Spiegelman, C. Byrne, D.J. Hunter, and G.A. Colditz Validation of the Gail et al. model of breast cancer risk prediction and implications for chemoprevention J Natl Cancer Inst 93 2001 358 366
19. C. Parkes, N.J. Wald, P. Murphy, and et al. Prospective observational study to assess value of prostate specific antigen as screening test for prostate cancer BMJ 311 1995 1340 1343
20. A.J. Vickers, A.M. Cronin, G. Aus, and et al. A panel of kallikrein markers can reduce unnecessary biopsy for prostate cancer: data from the European Randomized Study of Prostate Cancer Screening in Goteborg, Sweden BMC Med 6 2008 19
21. L.A. Bradley, G.E. Palomaki, S. Gutman, D. Samson, and N. Aronson Comparative effectiveness review: prostate cancer antigen 3 testing for the diagnosis and management of prostate cancer J Urol 190 2013 389 398
22. A.D. Choudhury, R. Eeles, S.J. Freedland, and et al. The role of genetic markers in the management of prostate cancer Eur Urol 62 2012 577 587
23. D. Hessels, and J.A. Schalken The use of PCA3 in the diagnosis of prostate cancer Nat Rev Urol 6 2009 255 261
24. M. Johansson, B. Holmstrom, S.R. Hinchliffe, and et al. Combining 33 genetic variants with prostate-specific antigen for prediction of prostate cancer: longitudinal study Int J Cancer 130 2012 129 137
25. J.R. Prensner, A.M. Chinnaiyan, and S. Srivastava Systematic, evidence-based discovery of biomarkers at the NCI Clin Exp Metastasis 29 2012 645 652
26. G. Aus, J.E. Damber, A. Khatami, H. Lilja, J. Stranne, and J. Hugosson Individualized screening interval for prostate cancer based on prostate-specific antigen level: results of a prospective, randomized, population-based study Arch Intern Med 165 2005 1857 1861
27. B. Holmstrom, M. Johansson, A. Bergh, U.H. Stenman, G. Hallmans, and P. Stattin Prostate specific antigen for early detection of prostate cancer: longitudinal study BMJ 339 2009 b3537
28. S. Carlsson, M. Assel, D. Sjoberg, and et al. Influence of blood prostate specific antigen levels at age 60 on benefits and harms of prostate cancer screening: population based cohort study BMJ 348 2014 g2296